human β defensin 2
Pre-clinical- Indications
- Necrotizing enterocolitis
Company intelligence / Profile preview
Defensin Therapeutics ApS
Denmark6sense.com ↗
- Ownership
- Private
- Development stage
- Preclinical
01
Overview
Defensin Therapeutics is developing recombinant defensin-based therapies targeting immune system diseases. Its lead program, hBD‑2 for acute graft versus host disease, is in preclinical development. Other programs have targeted asthma, inflammatory bowel disease, and metabolic syndrome but remain at the preclinical stage or are inactive.[4][5] No clinical results have been published to date.
- Therapeutic areas
- GastroenterologyMetabolic DisordersImmunologyPulmonology
- Modalities
- Recombinant polypeptidesPeptides (notably defensins, such as human β-defensin 2 and α-defensins)[4][5]
- Industry
- Biotech
02
Drug pipeline
2 assets1 more asset in the full pipeline.
Request access →03
Partnerships
Dr. Falk Pharma has been involved with human β‑defensins research alongside Defensin Therapeutics ApS on some indications.[5] No major pharma partnerships disclosed.
Beyond the preview
Go deeper on Defensin Therapeutics ApS.
Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.
Clinical trials
Full profile accessFollow clinical development from trial design and recruitment through results.
- Trial phase
- Status
- Readouts
Licensing & deals
Full profile accessExplore licensing agreements, acquisitions, and the assets behind each deal.
- Partners
- Deal terms
- Milestones
Funding history
Full profile accessTrace financing activity and the investors behind a company’s development.
- Funding rounds
- Investors
- Capital raised
Competitive landscape
Full profile accessCompare peer pipelines by target, modality, and therapeutic area.
- Peer companies
- Targets
- Pipeline overlap
Technologies & patents
Full profile accessExplore technology platforms and the patent landscape around relevant assets.
- Platforms
- Patents
- Assignees
Research & analysis
Full profile accessConnect company news and source material to the questions you’re investigating.
- Company news
- Sources
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on Defensin Therapeutics ApS.